#hatch-waxman-act

[ follow ]
#fda

Oral Arguments Preview: Teva v. Amneal Tests Scope of Orange Book Device Patent Listings

The Federal Circuit's decision in Teva v. Amneal could redefine pharmaceutical patent listing requirements under the Hatch-Waxman Act.
The ruling may impact how device patents related to drugs are treated in the FDA's Orange Book.

Understanding the Statute on Patent Term Extension

Hatch-Waxman Act enables patent term extensions to counteract premarket regulatory delays.

Oral Arguments Preview: Teva v. Amneal Tests Scope of Orange Book Device Patent Listings

The Federal Circuit's decision in Teva v. Amneal could redefine pharmaceutical patent listing requirements under the Hatch-Waxman Act.
The ruling may impact how device patents related to drugs are treated in the FDA's Orange Book.

Understanding the Statute on Patent Term Extension

Hatch-Waxman Act enables patent term extensions to counteract premarket regulatory delays.
morefda
#patent-law

Protecting Pharmaceutical Innovation in Brazil Despite the Lack of a Patent Linkage System

Litigation remains a viable strategy for ensuring market exclusivity despite limitations from the Bolar Exemption.

Teva v. Amneal: Orange Book Listing Requirements Under Scrutiny

The Federal Circuit's ruling may reshape patent listing practices under Hatch-Waxman, influencing generic drug market access.
The case challenges the suitability of listing device patents in the Orange Book regarding patent claims.
The ruling could define how device patents relate to broader patent strategies for pharmaceuticals.

Protecting Pharmaceutical Innovation in Brazil Despite the Lack of a Patent Linkage System

Litigation remains a viable strategy for ensuring market exclusivity despite limitations from the Bolar Exemption.

Teva v. Amneal: Orange Book Listing Requirements Under Scrutiny

The Federal Circuit's ruling may reshape patent listing practices under Hatch-Waxman, influencing generic drug market access.
The case challenges the suitability of listing device patents in the Orange Book regarding patent claims.
The ruling could define how device patents relate to broader patent strategies for pharmaceuticals.
morepatent-law

Call Off Chicken Little: The Sky is Not Falling for Skinny Labeling After GSK v. Teva

Generic companies using skinny labeling should not receive preferential treatment for inducement purposes, as consistent inducement laws should be applied uniformly.
[ Load more ]